Trial Profile
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Paclitaxel (Primary)
- Indications Anal cancer; Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 12 Jan 2024 Planned End Date changed from 27 Dec 2023 to 27 Dec 2024.
- 12 Jan 2024 Planned primary completion date changed from 27 Dec 2023 to 27 Dec 2024.
- 03 Sep 2022 Planned End Date changed from 26 Dec 2022 to 27 Dec 2023.